IJSS-published review finds that the novel biplanar expandable cage provides effective vertebral body slip or spondylolisthesis reduction and improvement in radiographic and clinical parameters with no reported subsidence, migration, or endplate violation IJSS-published review finds that the novel biplanar expandable cage provides effective vertebral body slip or spondylolisthesis reduction and improvement in radiographic and clinical parameters with no reported subsidence, migration, or endplate violation

Link:
Safe and Efficacious Treatment of Spondylolisthesis via MIS TLIF Approach with the FlareHawk® Expandable Cage

Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors

Go here to read the rest:
Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer

ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in AdultsZILXI demonstrated a favorable safety and tolerability profile for up to 52 weeks of treatmentEfficacy of ZILXI continued to develop for an additional 40 weeks of treatment after an initial treatment period of 12 weeks

See the original post:
VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of...

SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced a keynote lecture, an oral presentation and two posters at the 7th European Scientific Working Group on Influenza (ESWI) Influenza Conference, which takes place virtually Dec. 6-9, 2020.

See the original post:
Cidara Therapeutics to Present Preclinical Data for Influenza AVCs at the 7th ESWI Influenza Conference

WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in its REBUILD Phase 3 registrational clinical study evaluating INOpulse®, a pulsed inhaled nitric oxide therapy, as a potential treatment for fibrotic interstitial lung disease (fILD).

See the rest here:
Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial...

MONMOUTH JUNCTION, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab?for use in retinal?indications, announced today that it has received notification from Nasdaq that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of Outlook Therapeutics’ common stock has been at $1.00 or greater for 10 consecutive trading days. Accordingly, this matter is now closed.

View original post here:
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

- Meeting Highlights Include New Long-Term Data in Tuberous Sclerosis Complex -

See more here:
Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

Achieving lower costs, while increasing capacity Achieving lower costs, while increasing capacity

Read more:
Better Choice Showing Opportunity for Substantial Monetary Savings from Consolidation of Fulfillment Operations

Hamilton, Bermuda, December 1, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced positive efficacy data from testing AM-301 in vitro. AM-301 is a drug-free nasal spray being developed by the Company’s affiliate Altamira Medica for protection against airborne pathogens and allergens.

Read the original here:
Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection

SHANGHAI, China, Nov. 27, 2020 (GLOBE NEWSWIRE) -- ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), a leading integrated solutions provider in the non-medical health and wellness market in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2020 on Monday, November 30, 2020.

Read the original:
ECMOHO to Announce Third Quarter 2020 Unaudited Financial Results

Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis

The rest is here:
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

CAMBRIDGE, Mass., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.

Go here to read the rest:
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement...

Here is the original post:
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with...

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate at two upcoming virtual investor conferences in December, including:

View original post here:
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

SAN DIEGO, Nov. 27, 2020 (GLOBE NEWSWIRE) -- SmartPharm Therapeutics, Inc. (“SmartPharm”), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and developer of next-generation, non-viral gene therapy technologies, announced today that it has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) co-funded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop a rapid countermeasure to COVID-19. The contract would provide SmartPharm up to USD $34 million for development through Phase 2 clinical studies of a gene-encoded antibody (“Gene MAb”) that could enable rapid protection from and/or treatment of SARS-CoV-2 infection and COVID-19. Sorrento will seek further funding in support of the COVID Gene MAb program toward EUA (emergency use authorization) approval and large-scale manufacturing pending successful clinical studies.

Read the original here:
DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded...

MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences New York & Philadelphia Virtual Event on December 3 at 10:30 a.m. This panel will be moderated by Theresa Lavoie, Principal, Fish & Richardson and also feature panelists, Greg White, Senior Director, Global Market Access Policy – Janssen, Pharmaceutical Companies and Snehal Naik, Global Regulatory Affair- Advanced Therapies, Janssen R&D.

More here:
CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene...

TORONTO, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. (“Dialco”), today announced the details for the Company’s upcoming Virtual Investor Day, scheduled to be held on Friday, December 4, 2020 at 10:00 a.m. EST.

Read this article:
Spectral Medical to Host Virtual Investor Day on December 4, 2020

Read more here:
Tauriga Sciences Inc. Sets New Daily E-Commerce Records for Both: Revenue Generated [$9,514.49] and Individual Online Orders [103 Total]

– R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19 –

See the original post:
Ceapro Inc. Reports 2020 Third Quarter and Nine-Month Financial Results and Operational Highlights

Future References to Lead Drug Candidate for Alzheimer’s Disease Will Be Simufilam Future References to Lead Drug Candidate for Alzheimer’s Disease Will Be Simufilam

Original post:
USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’